Generated: April 25, 2017
|Title:||Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors|
|Abstract:||Disclosed is a novel enantiomeric synthesis cermamide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.|
|Inventor(s):||Hirth; Bradford H. (Littleton, MA), Siegel; Craig (Woburn, MA)|
|Assignee:||Genzyme Corporation (Cambridge, MA)|
|Filing Date:||Jul 16, 2002|
|Claims:||1. A compound represented by the following structural formula: ##STR32## the enantiomer of the compound, a salt of the compound, or a salt of the enantiomer, wherein: R.sub.4 is H.sub.2 or O; and R.sub.6 is represented by the following structural formula: ##STR33## wherein phenyl ring A is substituted or unsubstituted; or when R.sub.4 is H.sub.2, R.sub.6 can further be --H. |
2. The compound of claim 1 wherein phenyl ring A is unsubstituted.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.